A low CD34+ cell dose predicts relapse and death early following autologous blood stem cell transplantation

Hematology

Volumn 6, Issue 1, 2001, Pages 19-27

  Stewart, D A ^a   Guo, D ^a   Luider, J ^a   Auer, I ^a   Klassen, J ^a   Morris, D ^a   Chaudhry, A ^a   Brown, C ^a   Gluck S ^a   Russell, J A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Hematopoietic stem cell transplantation; Prognosis; Survival

Indexed keywords

CARBOPLATIN; CARMUSTINE; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MITOXANTRONE; NAVELBINE; THIOTEPA; VINBLASTINE;

ADOLESCENT; ADULT; AGE; AGED; APHERESIS; ARTICLE; AUTOTRANSPLANTATION; BREAST CANCER; BREAST METASTASIS; CANADA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CONTROLLED STUDY; DEATH; DISEASE ACTIVITY; FEMALE; GENDER; GERM CELL TUMOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; STATISTICAL MODEL; SURVIVAL; WHOLE BODY RADIATION;

EID: 0034800772     PISSN: 10245332     EISSN: None     Source Type: Journal    
DOI: 10.1080/10245332.2001.11746549     Document Type: Article

References (32)

1. The biology and clinical use of blood stem cells
2. The ISHAGE guidelines for CD34+ cell determination by flow cytometry
3. Quantitative CD34+ analysis may be used to guide peripheral-blood stem cell harvest
4. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients
5. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery
6. Peripheral blood stem cell mobilization for high dose chemotherapy
7. Factors affecting hematopoietic recovery after high dose therapy and autologous peripheral blood progenitor cell transplantation: A single centre experience
8. Factors predicting engraftment of autologous blood stem cells: CD34+ subsets inferior to the total CD34+ cell dose
9. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens
10. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies
11. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: The effect of leukemic burden, donor HLA matching and marrow cell dose
12. Role of CD34+ cells in engraftment after high dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue
13. CD34+ cell, CFU-GM and nucleated cell dose predict engraftment but not survival following autologous purged bone marrow transplantation (BMT), yet do not predict outcomes following CD6+ T-cell depleted allogeneic BMT
14. Importance of marrow dose on posttransplant outcome in acute leukemia: Models derived from patients autografted with mafosfamide-purged marrow at a single institution
15. Mobilization of high numbers of autologous blood stem cells for patients with AML is associated with poor outcome: Results of the EORTC-GIMEMA AML10 amended trial
16. Effect of nucleated marrow cell dose on relapse and survival in identical twin transplants for leukemia
17. Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centres
18. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation
19. The ability to mobilize stem cells after induction therapy as an on study prognostic factor in AML patients < 60 years
20. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation
21. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow
22. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation
23. Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma
24. Immune modulation in autologous bone marrow transplantation: Cyclosporine and gamma-interferon trial
25. Intensive chemotherapy with G-CSF mobilization yields improved peripheral blood progenitor cell (PBPC) collection, quicker recovery after high dose chemotherapy and reduces progression risk compared to G-CSF alone for mobilization
26. Successful PBSC mobilization with high dose G-CSF for patients failing a first round of mobilization
27. Comparison between once a day vs. twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBSC) in normal donors for allogeneic PBPC transplantation
28. Kinetic study of CD34+ cells during peripheral blood stem cell collections
29. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high risk breast cancer patients
30. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: A randomized, controlled trial
31. Management strategies for the hard-to-mobilize patient
32. Ex-vivo expansion of bone marrow progenitor cells for hematopoietic reconstitution following high dose chemotherapy for breast cancer